Characteristics of patients continuing and discontinuing nintedanib in the year following commencement
| Characteristic | Continued nintedanib | Discontinued nintedanib | p-value |
| Patients n | 85 | 69 | |
| Age at treatment commencement years | 69.6±8.2 | 73.0±7.0 | 0.007 |
| Male | 69 (81.2) | 55 (79.7) | 0.819 |
| FVC % predicted | 77.1±17.2 | 67.0±18.8 | 0.001 |
| DLCO % predicted | 45.2±14.6 | 40.6±14.8 | 0.07 |
| Domiciliary oxygen | 18 (21.2) | 26 (37.7) | 0.024 |
| Time since diagnosis months | 11.7±15.1 | 16.4±17.5 | 0.08 |
| Prior pirfenidone treatment | 23 (27.1) | 27 (39.1) | 0.112 |
Data are presented as mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.